Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 2
2022 3
2023 3
2024 6
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.
Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC. Acker F, et al. Eur J Cancer. 2025 Mar 11;218:115266. doi: 10.1016/j.ejca.2025.115266. Epub 2025 Jan 30. Eur J Cancer. 2025. PMID: 39893747 Free article. Review.
Central nervous system relapse after allogeneic HCT in FLT3-mutated AML.
Kouidri K, Acker F, Toenges R, Pfaff S, Lindner S, Riemann J, Werth M, Ajib S, Lang F, Steffen B, Oellerich T, Serve H, Cremer A, Bug G. Kouidri K, et al. Among authors: acker f. Ann Hematol. 2024 Dec;103(12):5387-5393. doi: 10.1007/s00277-024-06106-y. Epub 2024 Nov 26. Ann Hematol. 2024. PMID: 39589497 Free PMC article.
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR Inhibition.
Acker F, Klein A, Rasokat A, Eisert A, Kron A, Christopoulos P, Stenzinger A, Kulhavy J, Hummel HD, Waller CF, Hummel A, Rittmeyer A, Kropf-Sanchen C, Zimmermann H, Lörsch A, Kauffmann-Guerrero D, Schütz M, Herster F, Thielert F, Demes M, Althoff FC, Aguinarte L, Heinzen S, Rost M, Schulte H, Stratmann J, Rohde G, Büttner R, Wolf J, Sebastian M, Michels S; National Network Genomic Medicine Lung Cancer. Acker F, et al. Clin Lung Cancer. 2024 Dec;25(8):672-682.e5. doi: 10.1016/j.cllc.2024.07.012. Epub 2024 Jul 23. Clin Lung Cancer. 2024. PMID: 39153867 Free article.
Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell Engagers.
Kemper M, Soltani Germy P, Acker F, Luan J, Griesinger F, Tufman A, Kropf-Sanchen C, Overbeck TR, Bleckmann A, Blasi M. Kemper M, et al. Among authors: acker f. Oncol Res Treat. 2024;47(6):312-315. doi: 10.1159/000538662. Epub 2024 Apr 4. Oncol Res Treat. 2024. PMID: 38574467 Free article. No abstract available.
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer.
Althoff FC, Schäfer LV, Acker F, Aguinarte L, Heinzen S, Rost M, Atmaca A, Rosery V, Alt J, Waller CF, Reinmuth N, Rohde G, Saalfeld FC, Becker von Rose A, Möller M, Frost N, Sebastian M, Stratmann JA. Althoff FC, et al. Among authors: acker f. Front Oncol. 2023 Sep 22;13:1273478. doi: 10.3389/fonc.2023.1273478. eCollection 2023. Front Oncol. 2023. PMID: 37810988 Free PMC article.
16 results